F-group (family)
2006.1.6.2 Integrin_beta
Ligands and drugs
276
Member domains
201
with ligand contacts (≤ 4 Å)
72.8% of members
171
with DrugDomain annotations
62.0% of members
75
with a DrugBank compound
27.2% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 2006.1.6.2 belongs to X-group 2006 HAD domain-like, which binds 9.7 ligand superclasses per 20 proteins, broader than 91% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00141 | NAG | N-Acetylglucosamine | 39 |
| DB06472 | MWX | Fradafiban | 4 |
| DB00775 | AGG | Tirofiban | 3 |
| DB00145 | GLY | Glycine | 2 |
| DB00451 | — | Levothyroxine | 1 |
| DB02709 | — | Resveratrol | 1 |
| DB04863 | — | — | 1 |
| DB15598 | — | — | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CAmetal | CALCIUM ION | 130 |
| MGmetal | MAGNESIUM ION | 98 |
| MNmetal | MANGANESE (II) ION | 60 |
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 54 |
| CL | CHLORIDE ION | 14 |
| AGG | TIROFIBAN | 4 |
| I1F | {5-[N-(4-carbamimidoylbenzoyl)-4-nitro-L-phenylalanyl]-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-2-yl}acetic acid | 4 |
| I7R | (4-{[(5S)-3-{4-[(E)-imino(4-methylpiperazin-1-yl)methyl]phenyl}-4,5-dihydro-1,2-oxazol-5-yl]methyl}piperazin-1-yl)acetic acid | 4 |
| MWX | Fradafiban | 4 |
| NB9 | Lamifiban | 4 |
| XQS | sibrafiban (active form) | 4 |
| 0DU | N-(2,6-dichlorobenzoyl)-4-[1,6-dimethyl-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl]-L-phenylalanine | 2 |
| 15P | POLYETHYLENE GLYCOL (N=34) | 2 |
| 5YB | N-(4-carbamimidoylbenzoyl)-beta-alanyl-L-alpha-aspartyl-L-phenylalanine | 2 |
| A1D8D | (2~{S})-3-[2-azanylethanoyl-[3-oxidanyl-5-[(5-oxidanylpyrimidin-2-yl)amino]phenyl]carbonyl-amino]-2-(3-bromanyl-5-~{tert}-butyl-phenyl)propanoic acid | 2 |
| A1LU4 | 2-[(2~{R},5~{R},8~{S},11~{S})-11-(3-carbamimidamidopropyl)-7-methyl-3,6,9,12,15-pentakis(oxidanylidene)-5-(phenylmethyl)-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]ethanoic acid | 2 |
| A1LU7 | 2-[(2~{R},5~{R},8~{S},11~{S})-8-(4-azanylbutyl)-11-(3-carbamimidamidopropyl)-3,6,9,12,15-pentakis(oxidanylidene)-5-(phenylmethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]ethanoic acid | 2 |
| IR7 | (4-{[2-oxo-4-(piperidin-4-yl)piperazin-1-yl]acetyl}phenoxy)acetic acid | 2 |
| M6K | (4-{[(5S)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]methyl}piperazin-1-yl)acetic acid | 2 |
| MJX | {4-[4-(4-carbamimidoylphenyl)piperazin-1-yl]piperidin-1-yl}acetic acid | 2 |